Evidence map›Paper›PMID 39282901›Full record

ArticleJournal of chemotherapy (Florence, Italy)2025

Reversible chemoresistance of pancreatic cancer grown as spheroids.

Yoshihisa Matsushita, Alexis Norris, Yi Zhong, Asma Begum, Hong Liang, Marija Debeljak, Nicole Anders, Michael Goggins, Zeshaan A Rasheed, Ralph H Hruban and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chemotherapy (Florence, Italy), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yoshihisa MatsushitaDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Alexis NorrisDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Yi ZhongDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Asma BegumDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Hong LiangDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Marija DebeljakDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Nicole AndersDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Michael GogginsDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Zeshaan A RasheedDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Elizabeth D ThompsonDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.
Michelle A RudekDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Jun O LiuDepartment of Pharmacology, Johns Hopkins University, Baltimore, MD, USA.
Leslie CopeDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
James R EshlemanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Centre, Johns Hopkins University, Baltimore, MD, USA.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCRR NIH HHS S10 RR026824
6 · The paper itself

Abstract

Better

Indexed as

AdenocarcinomaAntineoplastic AgentsDrug Resistance, NeoplasmPancreatic NeoplasmsSpheroids, CellularAlbuminsApoptosisCell Culture TechniquesCell Line, TumorDeoxycytidineDiterpenesDocetaxelDrug Screening Assays, AntitumorEpoxy CompoundsErlotinib HydrochlorideGemcitabine130-nm albumin-bound paclitaxelAlbuminsAntineoplastic AgentsDeoxycytidineDiterpenesDocetaxelEpoxy CompoundsErlotinib HydrochlorideGemcitabinePaclitaxelPhenanthrenestriptolideAbraxanecancer associated fibroblasts (CAFs)chemosensitivitycombination drug therapymultidrug resistance (MDR)Organoidspancreatic cancer

Identifiers

PMID39282901
PMCPMC11910381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.